<?xml version="1.0" encoding="UTF-8"?>
<p id="p0030c">Over the past 5Â decades, the process of monitoring ongoing randomized clinical trials (RCTs) by means of an independent data monitoring committee (DMC) for safety and benefit has evolved [
 <xref rid="bib1" ref-type="bibr">1</xref>,
 <xref rid="bib2" ref-type="bibr">2</xref>]. In March of 2020, the World Health Organization (WHO) declared COVID-19 disease to be a pandemic and numerous trials began soon thereafter to provide timely evaluations of vaccines and therapeutics. This article discusses challenges that the COVID-19 trials bring to the DMC process, influenced by the speed at which the epidemic is spreading, patients are being recruited, and outcome data for benefit and risk are accumulating. The independent oversight provided by DMCs is perhaps even more important in trials for extreme emergencies such as the HIV/AIDS or coronavirus epidemics.
</p>
